Rajesh Krishna, PhD

Rajesh Krishna, PhDは、サターラ・ストラテジック・コンサルティングの医薬品開発科学特別研究員、ならびに希少疾患に関する統合プラクティス領域のリーダーです。With ~25 years of combined pharmaceutical industry and consulting experience, he has contributed to over 40 INDs; over 200 Phase 1/1b studies; and to the worldwide registration of several NDAs/BLAs. Raj received Ph.D in pharmaceutical sciences from the University of British Columbia, Canada and an MBA from Warwick Business School, UK. He is an elected fellow of the American Association of Pharmaceutical Scientists and a member of the editorial board of the Journal of Clinical Pharmacology. Raj is also a member of the IQ pediatrics working group and an extended member of the TREAT-NMD Advisory Committee for Therapeutics (TACT) committee. A prolific scientist, Raj has published about 90 peer-reviewed publications, a frequently invited speaker and educator, and edited or co-edited 4 books on new drug development. Rajの臨床薬理ブログの執筆者でもあります。